Tempest Therapeutics, Inc. (TPST): VRIO Analysis [Mar-2026 Updated]

Unlocking the secrets to Tempest Therapeutics, Inc. (TPST)'s enduring success starts here: this VRIO analysis cuts straight to the chase, evaluating the Value, Rarity, Inimitability, and Organization of its core assets to pinpoint its true competitive advantage. Discover immediately whether Tempest Therapeutics, Inc. (TPST) possesses resources that are truly difficult for rivals to copy and why they matter - read on below to see the full breakdown.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Amezalpat (TPST-1120) Clinical Data and Phase 3 Readiness

You’re looking at a promising asset in Amezalpat (TPST-1120), but the path from positive Phase 2 data to a launched drug is littered with capital requirements. Here is the breakdown based on the latest data we have through the second half of 2025.

Value: Potential to be a first-in-class oral PPAR$\alpha$ antagonist for HCC, supported by Phase 2 data showing a six-month median overall survival improvement.

The value proposition for Amezalpat is concrete, driven by the Phase 1b/2 MORPHEUS-LIVER trial results. This oral, selective Peroxisome Proliferator-Activated Receptor alpha (PPAR$\alpha$) antagonist showed a clear lift over the standard of care (SOC) combination of atezolizumab and bevacizumab. Specifically, the triplet therapy achieved a median Overall Survival (OS) of 21 months compared to 15 months for the control group, a six-month median improvement. Also, the confirmed Objective Response Rate (ORR) hit 30%, more than double the control arm’s 13.3%. That’s real clinical impact.

The FDA recognized this potential by granting both Orphan Drug Designation in January 2025 and Fast Track designation in February 2025 for this indication. This is the kind of data that gets regulators’ attention.

Rarity: The specific mechanism targeting PPAR$\alpha$ in this context, combined with positive Phase 2 data, is relatively unique among late-stage HCC candidates.

Honestly, the mechanism itself is what sets it apart right now. As of mid-2024, Amezalpat was the only PPAR$\alpha$ antagonist in active clinical development for oncology. Targeting this pathway to disrupt fatty acid oxidation (FAO) in cancer cells is a distinct approach compared to many other agents in the space. The combination of this unique target and the compelling survival data makes it rare in the current late-stage pipeline.

Imitability: The specific clinical data package and the underlying mechanism are hard to copy quickly, but the target pathway itself is known.

You can’t just whip up a similar drug overnight. The specific clinical data package - the 21 months vs. 15 months OS - is unique to Tempest Therapeutics and is difficult to replicate without running a similar, lengthy trial. However, the underlying target, PPAR$\alpha$, is a known biological pathway, so a well-funded competitor could eventually pursue similar strategies. The barrier to entry is the successful execution of the clinical program to date, not the pathway itself.

Organization: The company is organized to advance this asset, having completed the end-of-Phase II meeting with the FDA for a Phase 3 study.

Tempest Therapeutics has definitely cleared the organizational hurdles to move forward. They secured broad regulatory agreement with the FDA and EMA on the Phase 3 plan. The global Phase 3 study, TPST-1120-301, was planned to commence patient enrollment in the first quarter of 2025. Plus, they have a supply agreement with Roche to support the trial, which is a big operational plus.

Here’s the quick math on the current state: As of March 31, 2025, the cash position was $21.5 million, following a net loss of $10.9 million for the first quarter of 2025. What this estimate hides is the massive capital burn required for a global Phase 3 trial, which has been estimated to cost around $100 million.

Competitive Advantage: Temporary, as the Phase 3 trial requires significant funding that is currently uncertain without a partnership.

Right now, the advantage is temporary. The clinical data suggests a sustained competitive advantage is possible, but the immediate hurdle is financial. Tempest is actively exploring strategic alternatives, including partnerships or additional financing, to fund the pivotal development. A recent November 2025 announcement suggested a new acquisition and financing could extend the runway to mid-2027, but this is contingent on closing and execution. If onboarding for the Phase 3 trial takes longer than expected due to capital constraints, the window to establish a lead shrinks.

Here are the key financial/operational metrics:

Finance: draft 13-week cash view by Friday.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: TPST-1495 Dual EP2/4 Antagonist Program

TPST-1495 Dual EP2/4 Antagonist Program

Value

Offers a potential first-in-class oral therapy for Familial Adenomatous Polyposis (FAP), a niche area with no approved medical therapies.

• FAP prevalence in the US: approximately 1 in 5,000 to 10,000 individuals in the US.

Rarity

Dual antagonism of EP2/4 receptors is a specific approach that may offer superior benefit over single-target agents.

Imitability

The specific molecule and its development pathway are proprietary, but the general target class is being pursued by others.

Organization

The Phase 2 trial is structured to be run by the Cancer Prevention Clinical Trials Network, leveraging external infrastructure.

• FDA granted Orphan Drug Designation for TPST-1495 for FAP treatment.
• Orphan Drug Designation benefits include tax credits for clinical testing, potential fee waivers for FDA applications, and seven years of market exclusivity if approved.
• Received FDA “Study May Proceed” letter for the Phase 2 trial.
• Phase 2 study expected to begin in 2025.
• Data from the Phase 2 study expected in 2026.
• Trial is financially supported by the NCI's Division of Cancer Prevention.
• Primary efficacy objective: assess activity in reducing duodenal polyp burden after 6 months of treatment.

Competitive Advantage

Temporary, contingent on successful Phase 2 data expected in 2026.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Strategic Acquisition of Dual-CAR T Programs (TPST-2003)

Value

Diversifies pipeline with TPST-2003, a clinical-stage CD19/BCMA Dual-CAR T program targeting extramedullary disease (EMD) in relapsed multiple myeloma (rrMM). Expected data milestones include:

• Phase 1 data for rrMM expected in 2026.
• Phase 1 data for POEMs syndrome expected in 2027.
• Potential registrational study in rrMM in the U.S. planned to start in 2027.

Rarity

Acquisition of a clinical-stage CAR-T asset via an all-stock deal during a period where biopharma financings were down 59% in the first half of 2025.

Imitability

The specific Factor Bioscience assets and deal terms are unique to this transaction, which includes the transfer of global rights to TPST-2003 outside of China, India, Turkey, and Russia.

The transaction structure includes a change in executive leadership and specific compensation details:

• New President and CEO Matt Angel's annual base salary: $650,000.
• New President and CEO Matt Angel's annual target bonus: 50% of base salary (or $325,000).
• Outgoing CEO Stephen Brady's annual salary: $600,000.

Organization

The acquisition was executed with a simultaneous financing commitment designed to extend the financial runway to mid-2027. A closing condition requires a pre-closing equity financing to generate gross proceeds of at least $5.0 million.

Financial context at the time of the announcement:

• Cash and cash equivalents at end of Q3: $7.5 million.
• Negative EBITDA (last twelve months): $36.17 million.
• Current Ratio: 2.3.
• Market Capitalization (at announcement): $41 million.

Competitive Advantage

Sustained advantage is contingent on successful integration and clinical progression of the acquired cell therapy platform alongside existing assets like amezalpat (Phase 3-ready PPAR$\alpha$ Antagonist) and TPST-1495 (Phase 2 start expected near term).

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Collaboration with Roche for Amezalpat

Value

The collaboration, announced on October 10, 2024, provides access to a powerhouse partner for clinical study execution and supply of Tecentriq (Atezolizumab) for the planned pivotal HCC trial. Roche will supply Atezolizumab globally for the Phase 3 study. Tempest retains all commercial and development rights to Amezalpat. The combination therapy demonstrated a six-month improvement in median overall survival (OS) in the Phase 1b/2 study compared to the control arm.

Rarity

A collaboration with a major pharmaceutical company like Roche on a lead asset is a significant de-risking factor, especially given that Amezalpat is a clinical PPAR$\alpha$ antagonist with no currently approved competitors in this class by the FDA.

• Amezalpat has been granted both Orphan Drug and Fast Track designations by the U.S. Food and Drug Administration (FDA) for the treatment of HCC.
• The Phase 3 study timeline could potentially be shortened by eight months due to a pre-specified early efficacy analysis.

Imitability

The specific terms and history of the collaboration are unique to TPST. The current agreement builds upon a previous clinical partnership dating back to 2021. The positive data supporting the move to Phase 3 includes:

• Consistent survival benefit across key subpopulations.
• Increased objective response rate in patients with a beta-catenin gene mutation.

Organization

Tempest remains the principal sponsor and leads the pivotal study, retaining all development and commercial rights to Amezalpat, which is a strong organizational control point. The company ended the 2024 fiscal year with $30.3 million in cash and cash equivalents, compared to $39.2 million on December 31, 2023. Roche's Tecentriq generated sales of $2.14 billion for Roche in 2024.

Competitive Advantage

Sustained, as long as the collaboration agreement remains in effect and provides value, leveraging Roche's supply of Atezolizumab (Tecentriq), a drug with $2.14 billion in 2024 sales for Roche. Tempest's Net Loss for the year 2024 was $41.8 million, with Research and Development expenses at $28.5 million.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Regulatory Incentives: Orphan Drug and Fast Track Designations

Value: These designations (for Amezalpat and TPST-1495) offer potential market exclusivity periods and development incentives, boosting commercial value.

Rarity: Achieving multiple key designations across different assets is uncommon for a company of this size.

• The company secured ODD for two distinct pipeline assets: Amezalpat and TPST-1495.
• Amezalpat received both ODD and FTD from the FDA, accelerating its path for a serious condition with unmet medical need.

Imitability: Regulatory designations are granted by agencies and cannot be imitated, only earned through data submission.

The FTD for Amezalpat was granted based on positive data from the global randomized Phase 1b/2 MORPHEUS-LIVER trial.

Organization: The regulatory team successfully navigated the FDA and EMA processes to secure these valuable statuses.

• FDA Orphan Drug Designation (ODD) for Amezalpat granted in January 2025.
• FDA Fast Track Designation (FTD) for Amezalpat granted on February 10, 2025.
• FDA Orphan Drug Designation (ODD) granted for TPST-1495.
• EMA Orphan Drug Designation for Amezalpat also secured.

Competitive Advantage: Sustained for the duration of the exclusivity period granted by the regulatory bodies.

The FTD allows for an expedited review process with the eventual goal of full FDA approval.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Focused R&D and Cost Management Strategy

The analysis focuses on the strategic financial realignment executed by Tempest Therapeutics, Inc.

Focused R&D and Cost Management Strategy

Value:

• Reduced Q3 2025 Research and Development expenses to just $0.6 million from $7.6 million in Q3 2024, resulting in a quarterly decrease of $7.0 million, preserving capital.
• Year-to-date Research and Development expenses for the nine months ended September 30, 2025, were $12.1 million, down from $17.7 million in the same period in 2024.
• Net loss for Q3 2025 narrowed to $3.5 million from $10.6 million in Q3 2024.

Rarity:

• The sharp, strategic reduction in R&D spending by $7.0 million quarter-over-quarter, while maintaining focus on key assets, demonstrates focused operational discipline.

Imitability:

• The specific cost structure and spending priorities, driven by the decision to explore strategic alternatives, are internal operational decisions not easily copied by competitors.

Organization:

• Management demonstrated the ability to pivot quickly, pausing projects to focus on the Phase 2 trial for TPST-1495 in collaboration with the NCI.
• The company is advancing TPST-1495 into a Phase 2 study for Familial Adenomatous Polyposis (FAP) under the auspices of the Cancer Prevention Clinical Trials Network and funded by the National Cancer Institute (NCI).

Competitive Advantage:

• Temporary, as R&D spending must eventually increase to advance the pipeline past Phase 2/3 milestones for assets like amezalpat (TPST-1120) in first-line HCC.
• Cash and cash equivalents decreased to $7.5 million by September 30, 2025, from $30.3 million at the end of 2024, indicating pressure on the financial runway supporting future development.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Extended Financial Runway to Mid-2027

Extended Financial Runway to Mid-2027

Value: The combination of the all-stock acquisition and the investment commitment from Factor Bioscience is projected to extend Tempest Therapeutics' cash runway to mid-2027. This funding is anticipated to cover key development phases and data milestones slated for 2026 and 2027.

Rarity: Securing a runway extension to mid-2027 through a simultaneous all-stock acquisition and an investment commitment from the counterparty (Factor) represents a significant achievement in the late 2025 funding climate.

Imitability: The specific financing structure, which couples an asset acquisition with a runway extension commitment via an investment from the seller, is unique to TPST's situation following the announcement on November 19, 2025.

Organization: The company executed a complex transaction involving the acquisition of clinical-stage CD19/BCMA Dual-CAR T programs (TPST-2003) and securing financing concurrently to address cash burn and fund operations through mid-2027.

Competitive Advantage: Temporary, as the extended runway is finite and contingent upon hitting value-creating milestones or securing further financing beyond mid-2027.

Key financial and transaction metrics supporting the runway extension:

The pipeline expansion includes:

• Acquisition of TPST-2003, a clinical-stage CD19/BCMA dual-CAR T program designed for extramedullary disease (EMD).
• Expansion of the existing pipeline which includes amezalpat (TPST-1120), which is Phase 3-ready, and TPST-1495, with a Phase 2 start expected near term.
• Potential to pursue a registrational study in rrMM in the U.S. starting in 2027.

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: New Leadership with Cell Therapy and IP Expertise

New Leadership with Cell Therapy and IP Expertise

The incoming President and CEO, Dr. Matt Angel, brings deep expertise in cell therapy development and holds over 150 patents covering mRNA, nucleic acid delivery, gene editing, and cell reprogramming technologies.

A CEO with such a strong, relevant scientific and intellectual property background is rare, especially following a major cell therapy acquisition. Dr. Angel previously led Factor Bioscience Inc. as co-founder and CEO since 2011 and led Brooklyn Immunotherapeutics as CEO from 2022-2023.

The specific combination of Dr. Angel's background and the existing team is not easily replicated. Dr. Angel is a co-founder of cell therapy companies Novellus Therapeutics (founded 2014; sold 2021) and Exacis Biotherapeutics (founded 2020; sold 2023).

The management transition is timed with the strategic acquisition, aligning leadership with the expanded, diversified pipeline. The all-stock transaction to acquire dual-targeting CAR-T programs from Factor Bioscience is expected to close in early 2026. The company expects existing cash and an investment commitment from Factor to extend its operational runway to mid-2027.

Sustained, as leadership quality and IP strategy are foundational to long-term value creation.

Key Data Points Related to Leadership and Pipeline Expansion:

The expanded pipeline now includes:

• TPST-2003: Clinical-stage CD19/BCMA dual-CAR T program targeting extramedullary disease (EMD).
• Amezalpat (TPST-1120): PPAR$\alpha$ antagonist, Phase 3-ready, with positive data showing a six-month improvement in median overall survival (OS) in first-line HCC when combined with atezolizumab and bevacizumab compared to standard of care alone.
• TPST-1495: Dual Ep2/4 Antagonist, Phase 2 start expected near term. Received Orphan Drug Designation in March 2025 for Familial Adenomatous Polyposis (FAP).

Tempest Therapeutics, Inc. (TPST) - VRIO Analysis: Platform for Targeted and Immune-Mediated Small Molecule Therapies

The analysis below is based on the platform underpinning candidates such as Amezalpat (TPST-1120) and TPST-1495.

The projection is drafted incorporating the following latest reported financial figures as of the end of Q3 2025:

• Cash and cash equivalents balance as of September 30, 2025: $7.5 million,.
• Net proceeds from June 2025 registered direct offering (YTD Q3 2025): $4.1 million.
• Net proceeds from at-the-market offering program (YTD Q3 2025): $2.8 million.
• Total net proceeds from financing activities reported for the nine months ended September 30, 2025: The sum of the two noted proceeds is $6.9 million.
• Cash used in operating activities for the nine months ended September 30, 2025: $23.2 million.